Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1623 1673 1699 1759
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17926809 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 18920285 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | Final Rejection | The Regents of the University of California |
| 18274823 | METHODS OF TREATING CANCERS USING STING AGONISTS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18262176 | Combination Therapy Schedules to Treat Cancer | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18858394 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 17960501 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING RETINAL DAMAGE IN GLAUCOMA | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 18937981 | Compositions and Methods to Protect and Enhance Structural and Functional Integrity of the Intestinal Glycocalyx | Final Rejection | Zhongke Runxin (Suzhou) Biological Technology Co., Ltd. |
| 18271750 | ADHESIVE COMPOSITION AND PRESSURE-SENSITIVE ADHESIVE TAPE | Final Rejection | NITTO DENKO CORPORATION |
| 18214162 | WATER-SOLUBLE DIETARY FIBER, USE THEREOF IN PREPARATION OF MEDICAMENT THAT PROMOTES METABOLISM OF ELLAGIC ACID INTO UROLITHIN A, AND PHARMACEUTICAL COMPOSITION | Non-Final OA | ZHEJIANG UNIVERSITY |
| 17180049 | COMPOSITIONS OF SOLUBLE BETA GLUCAN AND RELATED METHODS | Final Rejection | KEMIN INDUSTRIES, INC. |
| 18020227 | ADENOSINE-CONTAINING COMPOSITION AND METHOD FOR SUPPRESSING PRECIPITATION OF ADENOSINE | Non-Final OA | Shiseido Company, Ltd. |
| 17770410 | METHOD OF UTILIZING ULTRAFINE BUBBLES | Non-Final OA | Shiseido Company, Ltd. |
| 18265028 | Synthetic Compositions Comprising LNFP III and LSTa | Non-Final OA | FrieslandCampina Nederland B.V. |
| 18438500 | CROSS-LINKED POLYCARBOXYLATED POLYSACCHARIDES AND METHODS OF USE THEREOF | Non-Final OA | HALLURA LTD. |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | Non-Final OA | Pharmacosmos Holding A/S |
| 18411890 | ISOLATED BIOLOGICAL POLYSACCHARIDE COMPOUND, METHODS OF USE AND METHODS OF MANUFACTURE THEREOF | Final Rejection | TISSUE REPAIR LTD |
| 18032132 | HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS | Non-Final OA | THE U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18288754 | CONCENTRATION AND DIAFILTRATION OF OLIGONUCLEOTIDES | Non-Final OA | Hydranautics |
| 18552847 | METHOD FOR PRODUCING WATER-SOLUBLE POLYMER AND METHOD FOR PRODUCING WATER-ABSORBING RESIN | Non-Final OA | HAYASHIBARA CO., LTD. |
| 17348354 | GUAR HYDROXYPROPYLTRIMETHYLAMMONIUM CHLORIDE AND USES THEREOF IN HAIR TREATMENT COMPOSITIONS | Non-Final OA | SPECIALTY OPERATIONS FRANCE |
| 17838820 | Use Of Migalastat For Treating Fabry Disease In Pregnant Patients | Final Rejection | Amicus Therapeutics, Inc. |
| 18050242 | Method for obtaining low molecular weight heparins and low molecular weight heparins obtained therefrom | Final Rejection | LABORATORIOS FARMACEUTICOS ROVI, S.A. |
| 18273212 | COMPOUND FOR DEGRADING DEOXYRIBONUCLEIC ACID (DNA) POLYMERASE, AND USE THEREOF | Non-Final OA | TAIBIDI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. |
| 18082793 | SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS | Non-Final OA | GLYCOM A/S |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | Non-Final OA | Saga University |
| 18305446 | Preparation Method of Bifunctional Dextrin with High Embedding Rate and Rapid Absorption | Non-Final OA | QILU UNIVERSITY OF TECHNOLOGY |
| 18259761 | COMPOUND FOR TREATING NEURODEGENERATIVE DISEASES AND ITS ISOLATION METHOD THEREOF | Non-Final OA | SARAWAK BIODIVERSITY COUNCIL |
| 18121492 | HYALURONIC ACID BASED FORMULATIONS | Final Rejection | Allergan Industrie, SAS |
| 18178079 | PREBIOTIC COMPOSITION AND ITS USE | Non-Final OA | CP KELCO U.S., INC. |
| 18057714 | MODIFIED mRNA 5'-CAP ANALOGS | Non-Final OA | Nanjing GeneLeap Biotechnology Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy